Welcome to our searchable resource and literature collection on safer supply and related topics.
Found a broken link? Links do move around, so if you find one here that's broken, please let us know through the Contact form.
Welcome to our searchable resource and literature collection on safer supply and related topics.
Found a broken link? Links do move around, so if you find one here that's broken, please let us know through the Contact form.
Evaluate the population-level effects of OPSs and SCSs on acute health service use and mortality.
We report on a cost analysis study, using population level data to determine the emergency service costs avoided from emergency overdose management at supervised consumption services (SCS).
The aim of our study was to explore points of view of people who use drugs (PWUD) treated with Opioid Medication Therapies (methadone and buprenorphine), in a large multicentre sample.
To gain a nuanced understanding of provider perspectives on MOUD care delivery using telemedicine, we conducted semi-structured interviews with VHA providers who were using telehealth to deliver MO
Given the racist evolution of the war on drugs and the harm reduction (HR) movement, the aim of this study is to explore racism within harm reduction services through the perspectives of our partic
In the context of an overdose crisis linked to fentanyl, we used drug checking data to examine variability within the illicit opioid supply.
This is a summary of an independent assessment report prepared by Dale McMurchy Consulting based on information gathered through surveys and interviews with safer supply program leads, staff and pa
This research assessed the impact of COVID-19 on staff working at harm reduction and alcohol and other drug (AOD) services in Australia in the first 9 months of the pandemic.
Given the continued expansion of community pharmacy in the continuum of care, it is imperative to characterize alcohol use among pharmacy patients dispensed opioids in order to establish a foundati
This Evidence Brief asks: What is the evidence of effectiveness of supervised injectable opioid agonist treatment with diacetylmorphine (DAM) or hydromorphone (HDM) on treatment retention (i.e., in